NL1029828A1 - Conjugates of glycerol-branched polyethylene glycol and human growth hormone, methods for their preparation and methods for their use. - Google Patents

Conjugates of glycerol-branched polyethylene glycol and human growth hormone, methods for their preparation and methods for their use.

Info

Publication number
NL1029828A1
NL1029828A1 NL1029828A NL1029828A NL1029828A1 NL 1029828 A1 NL1029828 A1 NL 1029828A1 NL 1029828 A NL1029828 A NL 1029828A NL 1029828 A NL1029828 A NL 1029828A NL 1029828 A1 NL1029828 A1 NL 1029828A1
Authority
NL
Netherlands
Prior art keywords
methods
conjugates
glycerol
preparation
polyethylene glycol
Prior art date
Application number
NL1029828A
Other languages
Dutch (nl)
Other versions
NL1029828C2 (en
Inventor
Rory Francis Finn
Ned Roger Siegel
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL1029828(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of NL1029828A1 publication Critical patent/NL1029828A1/en
Application granted granted Critical
Publication of NL1029828C2 publication Critical patent/NL1029828C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
NL1029828A 2004-08-31 2005-08-30 Conjugates of glycerol-branched polyethylene glycol and human growth hormone, methods for their preparation and methods for their use. NL1029828C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60594504P 2004-08-31 2004-08-31
US60594504 2004-08-31

Publications (2)

Publication Number Publication Date
NL1029828A1 true NL1029828A1 (en) 2006-03-01
NL1029828C2 NL1029828C2 (en) 2006-10-20

Family

ID=35708806

Family Applications (1)

Application Number Title Priority Date Filing Date
NL1029828A NL1029828C2 (en) 2004-08-31 2005-08-30 Conjugates of glycerol-branched polyethylene glycol and human growth hormone, methods for their preparation and methods for their use.

Country Status (24)

Country Link
EP (1) EP1789092A2 (en)
JP (1) JP2008511610A (en)
KR (1) KR20070042567A (en)
CN (1) CN101010105A (en)
AP (1) AP2007003919A0 (en)
AR (1) AR050851A1 (en)
AU (1) AU2005278903A1 (en)
BR (1) BRPI0515118A (en)
CA (1) CA2577999A1 (en)
CR (1) CR8942A (en)
EA (1) EA200700380A1 (en)
EC (1) ECSP077281A (en)
GT (1) GT200500235A (en)
IL (1) IL181085A0 (en)
MA (1) MA28908B1 (en)
MX (1) MX2007002441A (en)
NL (1) NL1029828C2 (en)
NO (1) NO20071322L (en)
PE (1) PE20060654A1 (en)
TN (1) TNSN07078A1 (en)
TW (1) TW200621291A (en)
UY (1) UY29088A1 (en)
WO (1) WO2006024953A2 (en)
ZA (1) ZA200701802B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69838552T2 (en) 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
CA2359345A1 (en) 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1834963A1 (en) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
AU2006343689A1 (en) * 2006-05-12 2007-11-22 Dong-A Pharm.Co., Ltd. Polyethylene glycol-interferon alpha conjugate
JP2008069073A (en) * 2006-09-12 2008-03-27 Yokohama Tlo Co Ltd Lactoferrin conjugate and its manufacturing method
KR101079993B1 (en) 2006-11-17 2011-11-04 동아제약주식회사 Polyethylene glycol-G-CSF conjugate
CL2008002399A1 (en) 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
AU2009274738B2 (en) * 2008-07-23 2012-12-13 Hanmi Science Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends
JP5639585B2 (en) 2008-07-31 2014-12-10 ファーマエッセンティア コーポレイション Peptide-polymer conjugate
NZ592139A (en) * 2008-10-10 2013-03-28 Bionic Ear Inst Biodegradable polymer - bioactive moiety conjugates
US8535655B2 (en) 2008-10-10 2013-09-17 Polyactiva Pty Ltd. Biodegradable polymer—bioactive moiety conjugates
SI2340271T1 (en) 2008-10-10 2019-08-30 Polyactiva Pty Ltd. Polymer-bioactive agent conjugates
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
LT2393828T (en) 2009-02-03 2017-01-25 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
JP6086528B2 (en) 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Growth hormone with long-term in vivo efficacy
CN101831067A (en) * 2010-05-31 2010-09-15 王二新 Polyethylene glycol ester conjugate and application thereof in medicine preparation
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
CN102367290B (en) * 2011-04-26 2013-05-08 厦门赛诺邦格生物科技有限公司 Chain-functionalized multi-level branched polyethylene glycol and synthesis method thereof
DK2947111T3 (en) * 2013-01-17 2018-05-07 Xiamen Sinopeg Biotech Co Ltd MONOFUNCTIONAL BRANCHED POLYETHYLENE LYCOL AND BIORELATED SUBSTANCE MODIFIED BY SAME
CN104877127B (en) 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 A kind of eight arms polyethyleneglycol derivative, preparation method and its bio-related substance of modification
EP4282485A3 (en) 2014-11-06 2024-01-17 PharmaEssentia Corporation Dosage regimen for pegylated interferon
SG11202005952TA (en) * 2017-12-29 2020-07-29 Hoffmann La Roche Process for providing pegylated protein composition
WO2019129877A1 (en) 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Process for providing pegylated protein composition
WO2019129876A1 (en) * 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Process for providing pegylated protein composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
JP3092531B2 (en) * 1996-11-05 2000-09-25 日本油脂株式会社 Method for producing imidyl succinate-substituted polyoxyalkylene derivative
DE69838552T2 (en) * 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS
JP3921781B2 (en) * 1998-02-12 2007-05-30 日本油脂株式会社 Carboxyl group-containing polyoxyalkylene compound
CA2359345A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CN1608079A (en) * 2001-11-20 2005-04-20 法玛西雅公司 Chemically-modified human growth hormone conjugates
US7157546B2 (en) * 2002-09-09 2007-01-02 Nektar Therapeutics Al, Corporation Water-soluble polymer alkanals
JP4412461B2 (en) * 2002-11-20 2010-02-10 日油株式会社 Modified bio-related substance, production method thereof and intermediate
WO2004060406A2 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Polymeric reagents comprising a ketone or a related functional group
DK2644206T3 (en) * 2003-05-23 2019-06-11 Nektar Therapeutics PEG derivatives containing two PEG chains

Also Published As

Publication number Publication date
AP2007003919A0 (en) 2007-02-28
MX2007002441A (en) 2007-05-04
AR050851A1 (en) 2006-11-29
EA200700380A1 (en) 2007-10-26
EP1789092A2 (en) 2007-05-30
ECSP077281A (en) 2007-03-29
NL1029828C2 (en) 2006-10-20
WO2006024953A3 (en) 2007-01-18
MA28908B1 (en) 2007-10-01
CA2577999A1 (en) 2006-03-09
KR20070042567A (en) 2007-04-23
TW200621291A (en) 2006-07-01
UY29088A1 (en) 2006-03-31
CN101010105A (en) 2007-08-01
ZA200701802B (en) 2008-08-27
BRPI0515118A (en) 2008-07-01
IL181085A0 (en) 2007-07-04
NO20071322L (en) 2007-05-29
TNSN07078A1 (en) 2008-06-02
AU2005278903A1 (en) 2006-03-09
WO2006024953A2 (en) 2006-03-09
PE20060654A1 (en) 2006-08-12
JP2008511610A (en) 2008-04-17
GT200500235A (en) 2006-03-21
CR8942A (en) 2007-08-16

Similar Documents

Publication Publication Date Title
NL1029828A1 (en) Conjugates of glycerol-branched polyethylene glycol and human growth hormone, methods for their preparation and methods for their use.
NL1028837A1 (en) N-terminal mono-pegylated human growth hormone conjugates and process for their preparation.
EP3281956A3 (en) Human antibody drug conjugates against tissue factor
LTC1735348I2 (en) Antibody against Human Epidermal Growth Factor Receptor
IL181738A (en) Pharmaceutical formulations comprising anti her2 antibodies
EP1753380A4 (en) Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
WO2005074546A3 (en) Modified human growth hormone polypeptides and their uses
MA28734B1 (en) 2-CARBAMID-4-PHENYLTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
IL179633A0 (en) Drug compositions, fusions and conjugates
MA28575B1 (en) 1-AMINO-PHTHALAZINE DERIVATIVES, THEIR PREPARATION, AND THERAPEUTIC USE THEREOF
BRPI0607198A2 (en) composition, use of composition diseases treatment method, and pharmaceutical packaging
EP2173373A4 (en) Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
EP4025257A4 (en) Antibody-drug conjugate comprising antibody against human ror1, and use for the same
MA28343A1 (en) ARYLOXYALKYLCARBAMATE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
MA29017B1 (en) 2-AMIDO-4-PHENYLTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
TWI350287B (en) Acylaminothiazole derivatives, their preparation and their therapeutic application
IL180770A0 (en) Oxopiperidine derivatives, preparation and therapeutic use thereof
FR2866888B1 (en) ALKYLPIPERAZINE- AND ALKYLHOMOPIPERAZINE-CARBOXYLATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
MA28720B1 (en) TETRAHYDROISOQUINOLILSULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
IL180797A0 (en) Amino-tropane derivatives, preparation thereof and therapeutic use thereof
GB2458080B (en) Sterols modified by polyethylene glycol, the preparation and the use thereof
DK1791872T3 (en) Biotinylated hexadecasaccharides, pharmaceutical preparations and their use
TWI340642B (en) Acylaminothiazole derivatives, preparation and therapeutic application thereof
ITMI20042356A1 (en) ORODISPERSIBLE PHARMACEUTICAL COMPOSITION AND PROCEDURE FOR PREPARING IT
HK1107340A1 (en) 4-arylmorpholin-3-one derivatives, preparation and therapeutic use thereof

Legal Events

Date Code Title Description
AD1A A request for search or an international type search has been filed
RD2N Patents in respect of which a decision has been taken or a report has been made (novelty report)

Effective date: 20060616

PD2B A search report has been drawn up
VD1 Lapsed due to non-payment of the annual fee

Effective date: 20090301